Acerus Pharmaceuticals Corp ASPCQ

Healthcare

Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

OTCPK:ASPCQ - Post by User

Acerus Pharmaceuticals Corp > The job of the investor relations dept. at Acerus...

<< Previous

Bullboard Posts

Next >>

Comment by PitchinPennieson Jul 19, 2022 11:06am

110 Views

Post# 34834250

RE:RE:The job of the investor relations dept. at Acerus...

That would just be one more thing on the lengthy list of what they're missing. But Acerus leads in one category: Check out this report. In the Q2 2022 Share Price Performance Review, we get the recognition we deserve. "Notable decliners in the quarter include: Acerus Pharmaceuticals Corp. The stock declined 67.2% in the quarter, following a 1 for 200 share consolidation, effective April 29, and reported 1Q-2022 financial results." Yup, that's us. At the very bottom of the Tier Two league tables. Facing relegation to Tier Three, if there was such a thing. (The other name Tier Three goes by is "Bankruptcy.")

User image